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Abstract 
BACKGROUND: In the Oslo cardiovascular study of 1972-3 a 5-year randomized trial in mild to 
moderate hypertension was performed. Several changes in treatment practices have been 
recommended since that time. We followed the mortality patterns up to 40 years. 
METHODS: Invited to the Oslo study screening were 25915 middle-aged men and 16203 (63 %) 
participated. Reexaminations were done to select suitable participants into the trial. Men had blood 
pressure 150-179/95-109 mmHg and the active group (n=406) was treated with thiazides, alpha-
methyldopa and propranolol versus untreated controls (n=379). Cox regression analysis was used for 
statistical analyses. 
RESULTS There was no trend towards reduction in total mortality by treatment.  A nominally 
significant increase in risk of death at first myocardial infarction was observed in the trial treatment 
group across the follow-up period, HR=1.51 (1.01-2.25); P=0.042). The excess risk developed rapidly 
during the first 15 years, but the gap between the groups diminished to a large extent during the next 
15 years, but the curves stayed at a certain distance for the last 10 years. Cerebrovascular death tended 
to be non-significantly reduced, HR=0.85 (0.52-1.41).  
CONCLUSIONS: Drug treatment of mild hypertensive men initiated in the 1970s did not reduce 
mortality at first MI or total mortality. However, during the period (late 1980s and whole 1990s), 
when large changes in hypertension treatment practices occurred into regimes with more use of 
combination therapies including metabolically neutral drugs at lower doses, beneficial effects on MI 
mortality could be observed. 
KEYWORDS: mild hypertension, long-term mortality, randomized drug trial, antihypertensive 
treatment 
Word count: 242 
The Oslo study of cardiovascular disease (CVD) in 1972-3 was the first in a series of similar studies 
performed by the National Health Service in different counties of Norway.1 In several counties 
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screenings were repeated after some years and the data collected have provided much of the basic 
knowledge about cardiovascular disease (CVD) epidemiology in Norway.2-9 
One major purpose of the screening in Oslo was to recruit participants to two randomized controlled 
trials among supposedly healthy men with a high risk of developing CVD. The background was that 
myocardial infarction (MI) incidence and mortality had increased at all years from World War II and 
had reached epidemic proportions. Prevention and treatment of the major risk factors were regarded as 
cornerstones to stop the epidemic. One of the trials was a treatment trial of 785 mild to moderate 
hypertensive men who were randomized to drug treatment or no treatment. Drug treatment consisted 
mainly of hydrochlorothiazide 50 mg daily and in addition if necessary methyldopa twice daily was 
added. If side effects occurred propranolol up to 160 mg twice daily was given. The other was a 
combined diet and antismoking trial in men with high total serum cholesterol levels and 80 % 
smokers. Both trials stopped at the end of the 1970s and detailed results have been reported.10-11 In 
light of the drastic changes since the 1970s in dietary and smoking habits, the large exchange to 
modern and metabolically neutral antihypertensive drugs and the massive use of statins in secondary 
coronary prevention and other high-risk populations with a reduction of coronary mortality in middle 
aged men to less than a fourth, the long term mortality outcomes of the trials would be difficult to 
predict. We know of no randomized hypertension drug trial that has been followed with respect to 
cardiovascular and total mortality for up to 35 years after its close. 
Thus, the purpose of this study was to report up to 40 years survival results with respect to death at 
first MI, cerebrovascular and all-cause mortality in the mild to moderate hypertension trial. 
 
MATERIAL AND METHODS 
All men in Oslo born 1923-1932 were in 1972/73 invited to a screening examination for CVD. Of the 
25915 eligible 16203 (63 %) participated. They were asked to fill in a questionnaire about prevalent 
CVD and diabetes. Those without such diseases were called healthy men and in them two 
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examinations followed to select suitable participants to two planned randomized trials 3. In the mild to 
moderate hypertension trial men with blood pressure 150-179/95-109 mmHg were included. 
Men with a higher blood pressure than those included in the trial were referred to the general practice 
system. The trial has previously been followed up with respect to coronary morbidity and mortality up 
to 10 years 12. The survivors (n=12764) in the screened population were invited to a second screening 
examination in year 2000. However, only 6014 men (45 %) of the invited participated and among the 
trial groups only 144 (35.2 %) and 134 (35.9 %) attended in the active and control group respectively. 
The present study is extended as a survey only to December 31th 2011 with respect to mortality at 
first MI, cerebrovascular and total mortality. Thus, no morbidity data other than prevalence of some 
diseases at the year 2000 screening were available through the whole follow up period. Statistics 
Norway added mortality data to the Oslo study data file according to permissions given by the Data 
Inspectorate and tax authorities, Department of health and the project was approved by the regional 
ethics committee for medical research. 
STATISTICAL ANALYSIS 
Rates per 1000 observation years and differences between rates with 95 % confidence limits were 
calculated. Cox proportional hazards regression models were used and time to death, time to death at 
first MI or time to cerebrovascular death were dependent variables. Group codes were exposure 
factors. Hazard ratios were calculated with 95 % confidence limits. The log rank test was used to test 
for differences between treatment groups with respect to survival. Kaplan-Meier curves were made by 
the STATA 13 software. 
 
RESULTS 
Table 1 shows some risk factors at screening in year 1972-73 by treatment group. They were 
fairly balanced as could be expected by design and demonstrate a population with normal 
bodyweight and mild to moderate blood pressure levels. The daily smoking proportion was 
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just above the average as compared to the whole screened population (data not given). When 
these men were invited to a new screening in year 2000 many had died and many declined to 
participate once more, but Table 2 gives an indication that groups were still fairly balanced 
on major coronary risk factors.  In this selected group the level of systolic blood pressure was 
still high, but also glucose stayed somewhat elevated.  Table 3 demonstrates small 
differences between proportions of men with experienced diabetes, MI or stroke by treatment 
group and so do use of antihypertensive or cholesterol lowering drugs. 
The hypertension trial treatment group had a nominally significant increased risk of death at first MI 
as compared to controls (HR=1.51; 95 % CI: 1.01-2.25; P=0.042), Figure 1. The risk difference 
developed proportionally the first 15 years. In the next 15 years from late 1980s to beginning of year 
2000s the gap narrowed. During the last 10 years curves went more parallel. Cerebrovascular death 
was non-significantly reduced, HR=0.87 (0.52-1.43), but number of such deaths was only 61.Total 
mortality was similar between the two treatment groups throughout the follow-up period, Figure 2.  
 
DISCUSSION 
This study showed an excess MI mortality risk, a slight and non-significant decrease in 
cerebrovascular death and equal total mortality by active treatment as compared to control. 
Unfortunately, the negative development of death at first MI continued in the hypertension trial 
participants up to 40 years of follow-up. The trend at close out of the trial was also confirmed at 10 
years follow-up 12. However, after about 15 years of follow up, the gap between the curves seemed to 
shrink for the next 15 years, but continued later on without fully catching up the lower risk in the 
control group. The interpretation of this finding is difficult since no regular clinical follow up was 
made on these men. Our data only stems from a mortality survey follow up at end of 2011. In year 
2000 the re-screened population among the survivors had a low (45 %) participation frequency and 
this was even lower in the trial participants due to their higher mortality.  Among these the prevalence 
6 
 
of drug treatment was 80.9 % in the active and 82.4 % in the control group men. Also other 
conventional risk factors were fairly equal in this selected subgroup at that time. This gives an 
indication that both groups were equally treated at that time and is thus consistent with the parallel MI 
survival curves observed during the last 10 years of follow-up. It is unknown to what degree old 
treatment modalities used in the hypertension trial have been exchanged with effective and more 
metabolically neutral antihypertensive drugs, since no such effort was made systematically. In 
Norway there was generally a great exchange of new drugs such as ACE inhibitors, angiotensin II 
blockers or calcium antagonists with more combination therapy each prescribed at lower doses during 
late 1980s and through the 1990s due to anticipated favorable results in large clinical trials. This is 
documented by prescription statistics during these years. 13 There was a high use of thiazides into the 
beginning of the 1980s, but then more calcium channel blockers were prescribed together with less 
use of thiazides that was almost not used in the period 1990 to about 2005, when new statements 
about use of thiazides as basic choice of drug were issued from the Government Health department 
but again abandoned in 2010. From about 1995 use of ACE and AII inhibitors increased rapidly and 
at the end of the follow up period defined daily dose per 100000 inhabitants per day of all 
hypertensive use (covering somewhat more diagnoses than pure hypertension) more than doubled in 
the population as compared to that in 1985 and more than 6-doubled from 1995 13. These massive 
changes in treatment modalities may have contributed but cannot be proved to the narrowing gap in 
heart disease mortality. However, not until 2002 came the first outcome trial showing newer treatment 
being favorable to older treatment 14 and this was substantiated in 2005 15.  
A possible reason for the meager effect of treatment on cerebrovascular mortality could be a dilution 
effect by initiating antihypertensive treatment in those control group men who developed a non-fatal 
cerebrovascular insult during the trial period. There it was documented that the incidence of stroke 
was significantly higher in the control as compared to the treatment group 11. Also, different 
antihypertensive drugs have different effects on cardiovascular endpoints even if blood pressure is 
reduced to the same level 14-17.  In addition, as mentioned above, antihypertensive treatment may have 
developed at a similar frequency the last years of follow up. 
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It came as no surprise that total mortality came out neutral between the two groups, since effects on 
cerebrovascular and MI mortality almost cancelled each other out. 
Meta analyses including both mild to moderate or only mild hypertension participants have so far not 
demonstrated significant benefits on coronary heart disease events but rather limited to 
cerebrovascular events 18-19. In the meta analysis including mild hypertension trials only and where the 
Oslo trial was not included cerebrovascular events was not significantly reduced and the effect on 
coronary heart disease events was in the adverse direction (Relative risk 1.12, 95 % CI 0.80-1.57) 19. 
Thus, our trial may have overestimated the negative effects of antihypertensive treatment on MI 
mortality as well as underestimated the effect on cerebrovascular events, but the crude estimates for 
coronary disease still lie within the confidence limits from the meta-analysis but outside of it for 
cerebrovascular events. Again, comparisons are hard to interpret since different treatment regimens, 
duration of follow up and endpoints were used.  We know of no other long-term follow up of 
randomized drug trials in mild to moderate hypertension after their close, but from our data it does not 
seem to be indifferent in the long term how blood pressure is reduced with regard to CHD prevention 
although this interpretation must be cautious. 
There is a need to get more data on the effect of antihypertensive treatment to reduce MI risk. 
. So far such treatment is largely shown to be beneficial to cerebrovascular disease and some 
combined endpoints of cardiovascular disease in mild to moderate hypertension. 
 
 
STUDY STRENGTHS AND LIMITATIONS 
Mortality follow-up in Norway is complete through its individual 11-digit person number and 
emigrants are censored at time of emigration. Efficacy on blood pressure reduction was high as 
documented in the first publication 11. There are several limitations to the study: lack of regular 
clinical follow up of these men makes it unknown how hypertension and other occurring diseases 
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have been treated in this period; cardiovascular morbidity data have not been available;  information 
from the rescreening of the surviving men in year 2000 only included 35 % of the original cohort due 
to higher than average mortality and selective attendance; the study was originally underpowered with 
no placebo control and was confined to men only.  
 
CONCLUSIONS 
In the mild to moderate hypertension trial the drug treated group had an excess MI risk during 
follow up.  A high degree of knowledge among medical practitioners regarding effective 
antihypertensive drug treatment in Norway has probably had an effect on the closing gap in MI 
mortality in the middle of the period. We learned that the correct mode of such treatment is of 
great importance. No differences between treatment groups were found with regard to total 
mortality.  
 
 
 
 
 
 
 
References 
1 Leren P, Askevold EM, Foss OP, et al. The Oslo Study. Cardiovascular disease in middle-aged and 
young Oslo men. Acta Medica Scandinavica.1975 (Suppl 588):1-38.  
9 
 
 
 2 Bjartveit K, Foss OP, Gjervig T, Lund-Larsen PG. The cardiovascular disease study in Norwegian 
counties. Background and organization. Acta Medica Scandinavica 1979;(Suppl 634):1-70. 
3 Lund-Larsen PG. ECG in Health and Disease. ECG findings in relation to CHD risk factors, 
constitutional variables and 16-year mortality in 2990 asymptomatic Oslo men aged 40-49 years in 
1972. The Oslo Study. ISM monograph series no 30. University of Tromsø. 1994. 
4 Tverdal A. A mortality follow-up of persons invited to a cardiovascular disease study in 5 areas in 
Norway (monograph). National Health Screening Service, Oslo. 1989. 
5 Thürmer H. Risk factors for, and 13-year mortality from cardiovascular disease by socioeconomic 
status: A study of 44690 men and 17540 women, ages 40-49. ISM Monograph series no 26. 
University of Tromsø, Norway. 1993. 
6 Holme I, Lund Håheim L, Hjermann I. Prediksjons funksjoner for 21 års utvikling av hjerteinfarkt fra 
Oslo undersøkelsen 1972/73. Tiddsskr Nor Lægeforen 2003; 123:1050-1054. 
7 Holme I, Tonstad S. Risikofaktorer og dødelighets oppfølging av Oslo undersøkelsen 1972-73. 
Tidsskr Nor Lægeforen 2011;131:456-460. 
8 Thelle DS, Førde OH. The Tromsø Heart Study. Methods and main results of the cross sectional 
study. Acta Med Scand 1976; 200:107-118. 
9 Førde OH, Thelle DS. The Tromsø Heart Study: risk factors for coronary heart disease related to the 
occurrence of myocardial infarction in first degree relatives. Am J Epidemiol 1977; 105:192-199. 
10 Hjermann I, Byre KV, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of 
coronary heart disease. Lancet 1981:1303-1310. 
10 
 
11 Helgeland A. The Oslo Study. Treatment of mild hypertension: A 5-year controlled drug trial. Am J 
Med 1980; 69:725-732. 
12 Leren P, Helgeland A. Coronary heart disease and treatment of hypertension. Am J Med 1986; 80 
(suppl 2A):3-6. 
13 Blix HS, Landmark K, Selmer R, Reikvam A. Forskrivning av antihypertensive legemidler 1975-
2010. Tidsskr Nor Lægeforen 2012; 122:1224-1228. 
14 Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan 
Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against 
atenolol. Lancet 2002; 359:995-1003.  
 
15 Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Collins R, Kjeldsen SE, Kristinsson A, 
McInnes GT, Mehlsen J, Nieminen M, O´Brien E, Östergren J . Prevention of cardiovascular events 
with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol 
adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 
895-906. 
 
16 Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk 
treated with regimens based on valsartan or amlodopine: the VALUE randomized trial. Lancet 
2004;363:2022.2031. 
 
17 Jamersen K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for 
hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428. 
 
11 
 
18 Gueyffier F1, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the 
estimate of therapeutic benefit. J Hum Hypertens. 1996 Jan;10(1):1-8.  
 
19 Diao D, Wright JM, Cundiff DK, Geuyffier F. Pharmacotherapy for mild hypertension. Cochrane 
Database Syst Rev. 2012 Aug 15;8:CD006742. doi: 10.1002/14651858.CD006742.pub2 
 
Funding: This study had no extra funding. 
Conflict of interest: IH has no disclosure to announce. SEK announces moderate honorarias for 
consulting (Bayer, Medtronic, Serodus, Takeda) and lectures (AZ, Bayer, Medtronic, MSD, Novartis, 
Takeda) and unrestricted grant support from AZ and Pronova, all directed to research accounts. 
Authorship: Both authors had access to the data and played a role in writing the manuscript. 
 
 
 
 
 
 
 
Table 1 Mean (SD) of some risk factors at screening in 1972-73 and in year 2000 by treatment 
group.* 
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Screening 1972-73 Treatment group (n=406) Control group (n=379) 
Systolic blood pressure (mmHg) 163.8 (11.6) 162.9 (10.4) 
Diastolic blood pressure (mmHg) 100.3 (10.1) 101.2 (9.1) 
Bodyweight (kg) 81.7 (11.5) 82.1 (11.2) 
Daily smoking (N, % Yes) 200 (52.8) 197 (48.5) 
Screening year 2000   
Attendants  (N, %) 144 (35.4) 134 (34.5) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Bodyweight (kg) 
Total serum cholesterol (mmol/L) 
Triglycerides (mmol/L) 
High density cholesterol 
(mmol/L) 
Serum glucose (mmol/L) 
157.6 (20.2) 
86.5 (11.2) 
82.4 (12.3) 
5.72 (1.11) 
1.87 (0.84) 
1.41 (0.40) 
6.08 (1.64) 
158.4 (19.7) 
84.6 (10.0) 
82.7 (13.0) 
5.74 (1.16) 
1.79 (0.96) 
1.42 (0.42) 
2.70 (6.56) 
Daily smoking (n, %) 
Previous smoking (n, %) 
Never smoking (n, %) 
21 (15.3) 
70 (51.1) 
46 (33.6) 
16 (11.1) 
91 (63.2) 
37 (25.7) 
* Number of valid measurements may vary due to some incompleteness in some variables. 
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Table 2 Disease prevalence and drug use at year 2000 by attending men per treatment group. 
 
Diseases and drug use Treatment group (n=144) Control group (n=134) 
Diabetes 22 (15.3) 14 (10.4) 
Myocardial infarction 24 (16.9) 27 (20.1) 
Cerebral stroke 12 (8.5) 15 (11.3) 
Use of antihypertensive drugs 
Use of cholesterol lowering 
drugs 
115 (80.4) 
45 (33.3) 
112 (82.4) 
39 (30.5) 
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Table 3 First myocardial infarction and total death risk through 40 years in the mild hypertension 
trial in Oslo  
Group MI deaths Rate per 1000 
obs years 
Number of 
deaths 
Death rate per 1000 obs 
years 
     
 
    Treatment (n=406) 
    Control (n=379) 
    Difference (95 % CI) 
   Hazard ratio                                          
 
63 
39 
 
 
5.3 
3.5 
-1.8 (-3.5-(-0.7)) 
1.51 (1.01-2.26)                
 
296 
272 
 
25.1 
24.7 
-0.4 (-44.6-37.2) 
1.02 (0.87-1.21) 
     
     
     
MI= myocardial infarction; CI= confidence interval.  
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Figur 2 Kaplan-Meier survival estimates of no MI in the mild hypertension trial by treatment group.  
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Figure 3 Kaplan-Meier survival estimates by treatment group in the mild hypertension trial. 
 
 
 
0.
00
0.
25
0.
50
0.
75
1.
00
0 10 20 30 40
Years of follow up
Drug treatment Control
